Patents by Inventor Edwin J. Wagena

Edwin J. Wagena has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CELL SUSPENSION FOR USE IN THE TREATMENT OF LOWER EXTREMITY PERIPHERAL ARTERY DISEASE
    Publication number: 20210161960
    Abstract: The present invention refers to a cell suspension of autologous or allogeneic, preferably autologous, adult bone marrow-derived white blood cells, preferably derived from the crest of the ilium (or iliac crest), enriched for mononuclear cells, meaning more than 25% of the white blood cells (WBCs) present in the cell suspension are mononuclear cells, and comprising: A. Mononuclear cells (MNC) selected from the list comprising or consisting of: i. A population of Lymphocytes; ii. A population of Monocytes; and iii. A population of Hematopoietic stem cells expressing CD34; and wherein the cell suspension further comprises: B. Granulocytes; for use in the treatment or amelioration of lower extremity peripheral artery disease.
    Type: Application
    Filed: November 23, 2020
    Publication date: June 3, 2021
    Inventors: Jonathan Robert Barclay Dupere, Liesbeth de Jong, Edwin J. Wagena, Inmaculada Concepción Herrera Arroyo
  • Cell suspension for use in the treatment of lower extremity peripheral artery disease
    Patent number: 10869886
    Abstract: The present invention refers to a cell suspension of autologous or allogeneic, preferably autologous, adult bone marrow-derived white blood cells, preferably derived from the crest of the ilium (or iliac crest), enriched for mononuclear cells, meaning more than 25% of the white blood cells (WBCs) present in the cell suspension are mononuclear cells, and comprising: A. Mononuclear cells (MNC) selected from the list comprising or consisting of: i. A population of Lymphocytes; ii. A population of Monocytes; and iii. A population of Hematopoietic stem cells expressing CD34; and wherein the cell suspension further comprises: B. Granulocytes; for use in the treatment or amelioration of lower extremity peripheral artery disease.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: December 22, 2020
    Assignees: REXGENERO BIOSCIENCES S.L., SERVICIO ANDALUZ DE SALUD, FUNDACIÜBLICA ANDALUZA PROGRESO Y SALUD
    Inventors: Jonathan Robert Barclay Dupere, Liesbeth de Jong, Edwin J. Wagena, Inmaculada Concepción Herrera Arroyo
  • CELL SUSPENSION FOR USE IN THE TREATMENT OF LOWER EXTREMITY PERIPHERAL ARTERY DISEASE
    Publication number: 20180055884
    Abstract: The present invention refers to a cell suspension of autologous or allogeneic, preferably autologous, adult bone marrow-derived white blood cells, preferably derived from the crest of the ilium (or iliac crest), enriched for mononuclear cells, meaning more than 25% of the white blood cells (WBCs) present in the cell suspension are mononuclear cells, and comprising: A. Mononuclear cells (MNC) selected from the list comprising or consisting of: i. A population of Lymphocytes; ii. A population of Monocytes; and iii. A population of Hematopoietic stem cells expressing CD34; and wherein the cell suspension further comprises: B. Granulocytes; for use in the treatment or amelioration of lower extremity peripheral artery disease.
    Type: Application
    Filed: August 28, 2017
    Publication date: March 1, 2018
    Inventors: Jonathan Robert Barclay Dupere, Liesbeth de Jong, Edwin J. Wagena